Scott McLean
Clinical Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Merkel cell carcinoma (MCC) is an aggressive disease with poor survival outcomes and increasing incidence. There is a clear and present need for enhanced understanding of cellular mechanisms of tumorigenesis, validation of robust genetic signatures predictive of aggressive disease, and novel informatics tools to simplify analysis of Merkel cell polyomavirus (MCPyV)–host genome interactions. Genomic DNA was harvested from 54 MCC tumors for exome sequencing and in-depth genetic profiling of a 226-gene panel. We further developed a robust informatics package (MCPyViewer) optimized for MCPyV integration site analysis with graphical output to simplify usability for end users. Finally, we assessed the prognostic impact of specific genetic signatures on MCC-specific survival in our cohort. Our study included 54 patients (n = 44 MCPyV positive), 11 (20.4%) of whom had died of MCC at last follow-up. Human genes altered at high frequency included LRP1B (n = 10, 18.5%), FAT1 (n = 9, 16.7%), KMT2D (n = 9, 16.7%), and RB1 (n = 7, 13.0%). In 36 of 44 (81.8%) MCPyV-positive tumors, we identified viral integration into the human genome with a median of two events per tumor. In six tumors, MCPyV integrated into Catalogue of Somatic Mutations in Cancer tier 1 or tier 2 cancer-related human genes. Implications: A combined genomics score incorporating tumor mutational burden and copy-number variation was strongly prognostic of MCC-specific survival controlling for lymph node metastases and tumor MCPyV status; thus, our study adds critical understanding to prognostic markers and tumorigenic mechanisms in MCC.
Year:
2025
Objectives To determine the relative 5‐year overall survival (OS) and 5‐year recurrence‐free survival (RFS) outcomes for adjuvant interferon therapy in the treatment of head and neck cutaneous melanoma (HNCM) with parotid gland involvement. Methods A retrospective cohort study was conducted at a single tertiary care institution to analyze patients undergoing parotidectomy for cutaneous head and neck melanoma involving the parotid gland from 2000 to 2014. Time‐to‐event analyses were performed using Kaplan–Meier curves with log‐rank p ‐values and Cox proportional hazards models. Results The sample consisted of 82 patients who underwent surgical resection of stage III HNCM with parotid involvement. The mean follow‐up was 67.8 months (SD 65) after diagnosis. Twenty‐one patients received adjuvant interferon therapy, 12 patients received adjuvant radiation therapy, and 49 patients received no adjuvant therapy. Crude 5‐year OS rates were 95.0% for interferon therapy, 33.3% for adjuvant RT, and 40.4% for no adjuvant therapy. Crude 5‐year RFS rates were 75.2%, 19.5%, and 40.8% respectively. In the fully adjusted model, adjuvant interferon therapy was associated with improved 5‐year OS compared to adjuvant RT (HR 0.10, 95% CI 0.011–0.837; p = 0.034). There was no significant association between adjuvant interferon therapy and 5‐year RFS in the fully adjusted model. Conclusion Adjuvant interferon therapy for surgically resected stage III cutaneous melanoma with parotid gland involvement may be associated with improved survival outcomes. These findings support the growing evidence for the use of immunotherapy in melanoma, and potentially a unique role for when melanoma involves the lymphatic‐rich parotid gland. Level of Evidence 3 Laryngoscope , 135:1098–1104, 2025
Year:
2025
Purpose: There is no current standard treatment regimen for carcinoma ex pleomorphic adenoma (CXPA) of the lacrimal gland. Neoadjuvant intraarterial cytoreductive chemotherapy (IACC) followed by multimodal therapy has achieved good locoregional control in adenoid cystic carcinoma of the lacrimal gland. The authors reviewed their experience with neoadjuvant IACC followed by multimodal therapy for CXPA of the lacrimal gland. Methods: Three patients with CXPA of the lacrimal gland treated with neoadjuvant ICAA therapy followed by multimodal therapy at the University of Michigan were retrospectively reviewed. Results: Three patients had stage T4cN0M0 CXPA of the lacrimal gland (American Joint Committee on Cancer 8th ed). The first patient underwent 2 cycles of neoadjuvant IACC followed by multimodal therapy (exenteration, chemoradiotherapy, and adjuvant systemic chemotherapy). At 10 years of follow-up, there was no local recurrence or systemic metastasis. The second patient underwent 1 cycle of neoadjuvant IACC with multimodal therapy (systemic chemotherapy, globe-sparing orbital surgery, and chemoradiotherapy). After 5-year follow-up, there was no local recurrence or systemic metastasis. The third patient underwent 2 cycles of neoadjuvant IACC followed by multimodal therapy (globe-sparing orbital surgery, chemoradiotherapy, and adjuvant systemic chemotherapy). After 2 years, he developed parotid and retromandibular metastasis and underwent total parotidectomy with total neck dissection followed by chemoradiation and systemic anti-androgen therapy. After 7 years, he did not have any local recurrence or systemic metastasis. Conclusions: Neoadjuvant IACC with multimodal therapies can achieve favorable outcomes with locoregional control and improve disease-specific survival in patients with locally invasive advanced-stage CXPA of the lacrimal gland.
Year:
2025
Year:
2025
Objective We assessed correlations between tumor carbonic anhydrase IX (CAIX) staining, as a marker of tumor hypoxia, and CD8 + T‐cell infiltration in a cohort of patients with advanced laryngeal squamous cell carcinoma undergoing a bioselection approach for definitive treatment. Study Design Retrospective cohort study. Setting Tertiary care hospital. Methods Patients with stage III to IV laryngeal squamous cell carcinoma treated under a bioselection paradigm were included. Immunohistochemistry for CD8 + T‐cells and CAIX was performed. Nonparametric tests and Kaplan‐Meier survival analyses were used to compare tumor CAIX status by clinicopathologic variables and CD8 + T‐cell infiltration and to evaluate the role of CAIX and combination CAIX/tumor infiltrating lymphocytes (TIL) category on survival. Results Our cohort included 92 patients (n = 68 [73.9%] supraglottic). No difference in CAIX staining was seen by tumor subsite, stage, and response to induction chemotherapy (all P > .05). Thirteen (14.1%) tumors were CAIX‐positive and showed significantly lower CD8 + T‐cell infiltration than CAIX‐negative tumors (18 [0‐62] vs 32 [0‐399], P = .028). Combination CAIX/TIL category was significantly associated with the likelihood of response (CAIX−/TIL[high] were less likely to respond) and in the group of responders, was predictive of a higher degree of tumor shrinkage (>80%). Conclusion CAIX staining correlates with reduced CD8 + T‐cell infiltration in patients with advanced laryngeal squamous cell carcinoma undergoing bioselection. The combination CAIX/TIL category is associated with the likelihood and degree of response to induction. The utility of CAIX status and other combination immune and hypoxia signatures as a biomarker of induction response and survival merits prospective evaluation.
Year:
2025
Comparison of t-TMB and CNV scores by clinicopathologic variables in overall cohort. Data shown as median (range) or n (%) for continuous and categorical variables, respectively. Wilcoxon Rank-Sum and Kruskal-Wallis tests used for comparison of categorical and continuous variables, respectively. Additionally, we saw no correlation between primary tumor Breslow depth (mm) and t-TMB (Pearson’s r = -0.131, [95% CI: - 0.412 – 0.173], p = 0.397) or CNV score (Pearson’s r = -0.102, [95% CI: - 0.387 – 0.201], p = 0.511). a Data for primary tumor LVI and Breslow depth available for 45 of 54 (83.3%) patients.
Year:
2025
Kaplan-Meier curves for MCC-specific survival by clinicopathologic variables. Patient sex (A), primary tumor site (B), AJCC 8th edition overall (C) and nodal (D) stage, tumor MCPyV status (E), and MCPyV physical state (for VP-MCC tumors) (F).
Year:
2025
Scatter plot illustrating the correlation between the number of MCPV alterations per tumor and the corresponding number of MCPV reads and Variant Allele Frequency (VAF) plots for all single nucleotide variants and insertions/deletions identified in the cohort.
Year:
2025
Merkel cell carcinoma (MCC) is an aggressive disease with poor survival outcomes and increasing incidence. There is a clear and present need for enhanced understanding of cellular mechanisms of tumorigenesis, validation of robust genetic signatures predictive of aggressive disease, and novel informatics tools to simplify analysis of Merkel cell polyomavirus (MCPyV)–host genome interactions. Genomic DNA was harvested from 54 MCC tumors for exome sequencing and in-depth genetic profiling of a 226-gene panel. We further developed a robust informatics package (MCPyViewer) optimized for MCPyV integration site analysis with graphical output to simplify usability for end users. Finally, we assessed the prognostic impact of specific genetic signatures on MCC-specific survival in our cohort. Our study included 54 patients ( n = 44 MCPyV positive), 11 (20.4%) of whom had died of MCC at last follow-up. Human genes altered at high frequency included LRP1B ( n = 10, 18.5%), FAT1 ( n = 9, 16.7%), KMT2D ( n = 9, 16.7%), and RB1 ( n = 7, 13.0%). In 36 of 44 (81.8%) MCPyV-positive tumors, we identified viral integration into the human genome with a median of two events per tumor. In six tumors, MCPyV integrated into Catalogue of Somatic Mutations in Cancer tier 1 or tier 2 cancer-related human genes. Implications: A combined genomics score incorporating tumor mutational burden and copy-number variation was strongly prognostic of MCC-specific survival controlling for lymph node metastases and tumor MCPyV status; thus, our study adds critical understanding to prognostic markers and tumorigenic mechanisms in MCC.
Year:
2025
Representative MCPyV integration events in MiOTO_4055 and MiOTO_4003 that fell within human oncogenes. Red arrow: MCPyV integration; Black segment: contigs assembled at integration events; Segments with black arrowhead: zoomed in contigs aligned to the human genome; Segments with red arrowhead: zoomed in contigs aligned to the MCPyV genome. Direction of segments indicate the strand of contigs aligned to. Note figure constructed using MCPyViewer.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (7)
Neeraj Chaudhary
Professor
University of Michigan Medical School
Ryan Mills
Professor
University of Michigan
Kelly L. Harms
University of Michigan
Matthew E. Spector
University of Pittsburgh Medical Center
Andrew Rosko
University of Michigan
Christopher Bichakjian
Professor and Chair
University of Michigan
J. Chad Brenner
Director Head and Neck Oncology Program
University of Michigan
Make your next move.
Prepare your application
Review drafts before you send them.